These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 9533981)

  • 41. Drug interactions of HIV protease inhibitors.
    Malaty LI; Kuper JJ
    Drug Saf; 1999 Feb; 20(2):147-69. PubMed ID: 10082072
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits.
    Flexner C
    Annu Rev Pharmacol Toxicol; 2000; 40():649-74. PubMed ID: 10836150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
    Marin-Niebla A; Lopez-Cortes LF; Ruiz-Valderas R; Viciana P; Mata R; Gutierrez A; Pascual R; Rodriguez M
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2035-42. PubMed ID: 17371813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. No tease this time--pros and cons of a long-awaited anti-HIV drug.
    Chang HE
    Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A review of low-dose ritonavir in protease inhibitor combination therapy.
    Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW
    Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients.
    Boffito M; Jackson A; Pozniak A; Giraudon M; Kulkarni R; Abelardo MC; Patel IH; Morcos PN
    Drugs R D; 2015 Mar; 15(1):141-53. PubMed ID: 25742730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir.
    Ives KJ; Jacobsen H; Galpin SA; Garaev MM; Dorrell L; Mous J; Bragman K; Weber JN
    J Antimicrob Chemother; 1997 Jun; 39(6):771-9. PubMed ID: 9222047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Saquinavir, the pioneer antiretroviral protease inhibitor.
    la Porte CJ
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1313-22. PubMed ID: 19737048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
    Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
    Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
    Antivir Ther; 2010; 15(6):817-29. PubMed ID: 20834094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decreased methadone effect after ritonavir initiation.
    Geletko SM; Erickson AD
    Pharmacotherapy; 2000 Jan; 20(1):93-4. PubMed ID: 10641980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice.
    Roberts NA; Craig JC; Sheldon J
    AIDS; 1998 Mar; 12(5):453-60. PubMed ID: 9543442
    [No Abstract]   [Full Text] [Related]  

  • 57. Principles and practice of HIV-protease inhibitor pharmacoenhancement.
    Moyle GJ; Back D
    HIV Med; 2001 Apr; 2(2):105-13. PubMed ID: 11737387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.
    Pettoello-Mantovani M; Kollmann TR; Raker C; Kim A; Yurasov S; Tudor R; Wiltshire H; Goldstein H
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1880-7. PubMed ID: 9303378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.
    Mammano F; Petit C; Clavel F
    J Virol; 1998 Sep; 72(9):7632-7. PubMed ID: 9696866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic enhancement of protease inhibitor therapy.
    King JR; Wynn H; Brundage R; Acosta EP
    Clin Pharmacokinet; 2004; 43(5):291-310. PubMed ID: 15080763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.